Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: A model of adverse antidepressant effects in human adolescents?

International Journal of Neuropsychopharmacology

Volumn 14, Issue 4, 2011, Pages 491-504

  Karanges, Emily ^a   Li, Kong M ^b   Motbey, Craig ^a   Callaghan, Paul D ^c   Katsifis, Andrew ^c   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Adolescent; antidepressant; neurochemistry; paroxetine; rat

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; PAROXETINE; SEROTONIN;

ADOLESCENT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DEVELOPMENTAL STAGE; DRUG BLOOD LEVEL; DRUG RESPONSE; EX VIVO STUDY; EXPERIMENTAL MODEL; LONG TERM CARE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PHYSICAL STRESS; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION;

ADOLESCENT; AGING; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; NEUROTRANSMITTER AGENTS; PAROXETINE; RATS; RATS, WISTAR; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 79960374578     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571100006X     Document Type: Article

References (79)

1. Alex K, Pehek E (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology & Therapeutics 113, 296-320. (Pubitemid 46149046)
2. Bar-Oz B, Einarson T, Einarson A, Boskovic R, et al. (2007). Paroxetine and congenital malformations : meta-analysis and consideration of potential confounding factors. Clinical Therapeutics 29, 918-926. (Pubitemid 47223423)
3. Bechtholt AJ, Valentino RJ, Lucki I (2006). Identifying neural substrates mediating chronic fluoxetine effects in the novelty-induced hypophagia test. Neuropsychopharmacology 31, S94-S95.
4. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, et al. (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density and mRNA level. Journal of Neuroscience 19, 10494-10501. (Pubitemid 30228055)
5. Birmaher B, Brent DA, Benson RS (1998). Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry 37, 1234-1238.
6. Bridge JA, Iyengar S, Salary BC, Barbe RP, et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment - a meta-analysis of randomized controlled trials. Journal of the American Medical Association 297, 1683-1696.
7. Brunello N, Blier P, Judd LL, Medlewicz J, et al. (2003). Noradrenaline in mood and anxiety disorders : basic and clinical studies. International Clinical Psychopharmacology 18, 191-202. (Pubitemid 36871870)
8. Bylund DB, Reed AL (2007). Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs? Neurochemistry International 51, 246-253. (Pubitemid 47374323)
9. Caballero J, Nahata MC (2005). Selective serotonin-reuptake inhibitors and suicidal ideation and behaviour in children. American Journal of Health-System Pharmacy 62, 864-867. (Pubitemid 40547372)
10. Carlson JN, Visker KE, Mielsen DM, Keller RW, et al. (1996). Chronic antidepressant drug treatment reducing turning behavior and increases dopamine levels in the medial prefrontal cortex. Brain Research 707, 122-126. (Pubitemid 26046588)
11. Carrey NJ, Dursun S, Clements R, Renton K, et al. (2002). Noradrenergic and serotonergic neuroendocrine responses in prepubertal, peripubertal, and postpubertal rats pretreated with desipramine and sertraline. Journal of the American Academy of Child and Adolescent Psychiatry 41, 999-1006. (Pubitemid 38338080)
12. Chen F, Lawrence AJ (2003). The effects of antidepressant treatment on serotonergic and dopaminergic systems in Fawn-Hooded rats : a quantitative autoradiography study. Brain Research 976, 22-29. (Pubitemid 36588532)
13. Clemens KJ, Cornish JL, Li KM, Hunt GE, et al. (2005). MDMA (Ecstasy) and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49, 195-207. (Pubitemid 40933758)
14. Crews F, He J, Hodge C (2007). Adolescent cortical development : a critical period of vulnerability for addiction. Pharmacology, Biochemistry, and Behavior 86, 189-199. (Pubitemid 46282057)
15. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 23, 238-245. (Pubitemid 34465544)
16. de Jong TR, Snaphaan LJAE, Pattij T, Veening JG, et al. (2006). Effects of chronic treatment of fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats. European Neuropsychopharmacology 16, 39-48. (Pubitemid 43005095)
17. Dean AJ, McDermott BM, Marshall RT (2006). Psychotropic medication utilization in a child and adolescent mental health service. Journal of Child and Adolescent Psychopharmacology 16, 273-285. (Pubitemid 43902424)
18. Delago PL (2004). How antidepressants help depression: mechanisms of action and clincial response. Journal of Clinical Psychiatry 65, S25-S30.
19. Detke MJ, Lucki I (1995). Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test : the effects of water depth. Behavioural Brain Research 73, 43-46. (Pubitemid 26007585)
20. DeVane CL (1999). Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cellular and Molecular Neurobiology 19, 443-466.
21. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E (2008). Serotonin-dopamine interaction : electrophysiological evidence. Progress in Brain Research 172, 45-71.
22. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E (2008). Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Progress in Brain Research 172, 7-44.
23. Dulawa SC, Hen R (2005). Recent advances in animal models of chronic antidepressant effects : the novelty-induced hypophagia test. Neuroscience and Biobehavioral Reviews 29, 771-783. (Pubitemid 40762599)
24. Dunlop BW, Nemeroff CB (2007). The role of dopamine in the pathophysiology of depression. Archives of General Psychiatry 64, 327-337. (Pubitemid 46376789)
25. Fleming GF (2007). The mental health of adolescents : assessment and management. Australian Family Physician 36, 588-593.
26. Frazer A (1997). Pharmacology of antidepressants. Journal of Clinical Psychopharmacology 17, 2S-18S. (Pubitemid 27145751)
27. Gobbi M, Crespi D, Foddi MC, Fracasso C, et al. (1997). Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn-Schmiedebergs Archives of Pharmacology 356, 22-28. (Pubitemid 27276148)
28. Goodman WK, Murphy TK, Storch EA (2007). Risk of adverse behavioural effects with pediatric use of antidepressants. Psychopharmacology 191, 87-96. (Pubitemid 46294949)
29. Gurtman CG, Morley KC, Li KM, Hunt GE, et al. (2002). Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. European Journal of Pharmacology 446, 89-96. (Pubitemid 34722561)
30. Hammad TA, Laughren T, Racoosin J (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 63, 332-339. (Pubitemid 43345358)
31. Harada T, Sakamoto K, Ishigooka J (2008). Incidence and predictors of activation syndrome induced by antidepressants. Depression and Anxiety 25, 1014-1019.
32. Hargreaves GA, McGregor IS (2007). Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcoholism: Clinical and Experimental Research 31, 1900-1907. (Pubitemid 47609640)
33. Hensler JG (2003). Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sciences 72, 1665-1682. (Pubitemid 36136072)
34. Hirano K, Seki T, Sakai N, Kato Y, et al. (2005). Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Research 1053, 154-161. (Pubitemid 41116801)
35. Hodes G, Yang L, Van Kooy J, Santollo J, et al. (2009). Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex. Neuroscience 163, 609-617.
36. Hrdina PD, Vu TB (1993). Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain : an autoradiographic study. Synapse 14, 324-331. (Pubitemid 23231011)
37. Jick H, Kaye JA, Jick SS (2004). Antidepressants and the risk of suicidal behaviours. Journal of the American Medical Association 292, 338-343.
38. Kapornai K, Vetro A (2008). Depression in children. Current Opinion in Psychiatry 21, 1-7. (Pubitemid 351339800)
39. Keller MB, Ryan ND, Strober M, Klein RG, et al. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomised, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 40, 762-772. (Pubitemid 32595260)
40. Kindlundh-Hogberg AMS, Schioth HB, Svenningsson P (2007). Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain. Neurotoxicology 28, 1158-1169. (Pubitemid 350026594)
41. Koks S, Beljajev S, Koovit I, Abramov U, et al. (2001). 8-OH-DPAT, but not deramciclane, antagonises the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology 153, 365-372. (Pubitemid 32125821)
42. Kovaevi T, Skelin I, Diksic M (2010). Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats. Synapse 64, 231-240.
43. Kugaya A, Seneca NM, Snyder PJ, Williams SA, et al. (2003). Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28, 413-420.
44. Li KM, Thompson MR, McGregor IS (2004). Rapid quantification of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography - ultraviolet absorbance detection. Journal of Chromatography, B: Biomedical Sciences and Applications 804, 319-326. (Pubitemid 38481707)
45. Luby JL (2009). Early childhood depression. American Journal of Psychiatry 166, 974-980.
46. Malkesman O, Weller A (2009). Two different putative genetic models of childhood depression - A review. Progress in Neurobiology 88, 153-169.
47. Mann JJ, Brent DA, Argano V (2001). The neurobiology and genetics of suicide and attempted suicide : a focus on the serotonergic system. Neuropsychopharmacology 24, 467-477. (Pubitemid 32244308)
48. Mann JJ, Emslie GJ, Baldessarini RJ, Beardslee W, et al. (2006). ACNP task force report on SSRIs and suicidal behaviour in youth. Neuropsychopharmacology 31, 473-492. (Pubitemid 43276964)
49. Mant A, Rendle VA, Hall WD, Mitchell PB, et al. (2004). Making new choices about antidepressants in Australia: the long view 1975-2002. Medical Journal of Australia 181, S21-S24. (Pubitemid 39341672)
50. Mason SS, Baker KB, Davis KW, Pogorelov VM, et al. (2009). Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. European Journal of Pharmacology 602, 306-315.
51. McCormick CM, Mathews IZ, Thomas C, Waters P (2010). Investigations of HPA function and the enduring consequences of stressors in adolescence in animal models. Brain and Cognition 72, 73-85.
52. Millan MJ (2004). The role of monoamines in the actions of established and novel antidepressant agents: a critical review. European Journal of Pharmacology 500, 371-384. (Pubitemid 39304021)
53. Miura H, Kitagami T, Ozaki N (2007). Suppressive effect of paroxetine, a selective serotonin reuptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefronal cortex of mice. Synapse 61, 698-706. (Pubitemid 47122741)
54. Murrin LC, Sanders JD, Bylund DB (2007). Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain : implications for differential drug effects on juveniles and adults. Biochemical Pharmacology 73, 1225-1236. (Pubitemid 46413183)
55. Newman ME, Shalom G, Ran A, Gur E, et al. (2004). Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors : regional differences and effects of WAY-100635. European Journal of Pharmacology 486, 25-30. (Pubitemid 38130157)
56. Oh J-E, Zupan B, Gross S, Toth M (2009). Paradoxical anxiogenic response of juvenile mice to fluoxetine. Neuropsychopharmacology 34, 2197-2207.
57. Olfson M, Marcus SC, Shaffer D (2006). Antidepressant drug therapy and suicide in severely depressed children and adults. Archives of General Psychiatry 63, 865-872. (Pubitemid 44188479)
58. Owens MJ, Knight DL, Nemeroff CB (2000). Paroxetine binding to the rat norepinephrine transporter in vivo. Biological Psychiatry 47, 842-845. (Pubitemid 30254058)
59. Paus T (2005). Mapping brain maturation and cognitive development through adolescence. Trends in Cognitive Sciences 9, 61-68.
60. Pellis SM, Pellis VC (1997). The prejuvenile onset of play fighting in laboratory rats (Rattus norvegicus). Developmental Psychobiology 31, 193-205. (Pubitemid 127465941)
61. Prisco S, Esposito E (1995). Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. British Journal of Pharmacology 116, 1923-1931.
62. Richelson E (1996). Synaptic effects of antodepressants. Journal of Clinical Psychopharmacology 16, 1S-9S.
63. Robertson HT, Allison DB (2009). Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS One 4, e7312.
64. Ryding E, Lindstrom M, Traskman-Bendz L (2008). The role of dopamine and serotonin in suicidal behaviour and aggression. Progress in Brain Research 172, 307-315.
65. Sekine Y, Sukuzi K, Ramachandran PV, Blackburn TP, et al. (2007). Acute and repeated administration of fluoxetine, citalopram and paroxetine significantly alters the activity of midrain dopamine neurons in rats : an in vivo electrophysiological study. Synapse 61, 72-77. (Pubitemid 44927730)
66. Sillaber I, Panhuysen M, Henniger MSH, Ohl F, et al. (2008). Profiling of behavioural changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology 200, 557-572.
67. Spear LP (2000). The adolescent brain and age-related behavioural manifestations. Neuroscience and Biobehavioural Reviews 24, 417-463. (Pubitemid 30243061)
68. Spear LP (2007). Assessment of adolescent neurotoxicity: rationale and methodological considerations. Neurotoxicology and teratology 29, 1-9. (Pubitemid 46205164)
69. Stone M, Laughren T, Jones ML, Levenson M, et al. (2009). Risk of suicidality in clinical trials of antidepressants in adults : analysis of proprietary data submitted to US Food and Drug Administration. British Medical Journal 339, b2880.
70. Tanda G, Carboni E, Frau R, Di Chiara G (1994). Increase of extracellular dopamine in the prefrontal cortex : a trait of drugs with antidepressant potential? Psychopharmacology 115, 285-288. (Pubitemid 24207795)
71. Thompson MR, Li KM, Clemens KJ, Gurtman CG, et al. (2004). Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA (ecstasy) in rats. Neuropsychopharmacology 29, 694-704. (Pubitemid 38402477)
72. Thor DH, Holloway WRJ (1984). Social play in juvenile rats : a decade of methodological and experimental research. Neuroscience and Biobehavioral Reviews 8, 455-464. (Pubitemid 15155158)
73. Titier K, Castaing N, Scotto-Gomez E, Pehourcq F, et al. (2003). High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. Therapeutic Drug Monitoring 25, 581-587. (Pubitemid 37238892)
74. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ (2008). Efficacy of antidepressants in juvenile depression: meta-analysis. British Journal of Psychiatry 193, 10-17. (Pubitemid 351946803)
75. Wegerer V, Moll GH, Bagli M, Rothenberger A, et al. (1999). Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. Journal of Child and Adolescent Psychopharmacology 9, 13-24.
76. Weissman MM, Wolk S, Goldstein RB, Moreau D, et al. (1999). Depressed adolescents grown up. Journal of the American Medical Association 281, 1707-1713. (Pubitemid 29226480)
77. Whittington CJ, Kendall T, Fonagy P, Cottrell D, et al. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published vs. unpublished data. Lancet 363, 1341-1345. (Pubitemid 38529872)
78. Yadid G, Friedman A (2008). Dynamics of the dopaminergic system as a key component to the understanding of depression. Progress in Brain Research 172, 265-286.
79. Yamauchi M, Miyara T, Matsushima T, Imanishi T (2006). Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Research 1067, 164-169. (Pubitemid 43133085)